Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
P. Brouwer, T. Caniels, K. van Straten, J. Snitselaar, Y. Aldon, S. Bangaru, J. Torres, N. Okba, M. Claireaux, G. Kerster, A. Bentlage, M. van Haaren, D. Guerra, J. Burger, E. Schermer, K. Verheul, N. van der Velde, A. van der Kooi, J. van Schooten, M. van Breemen, T. Bijl, K. Sliepen, A. Aartse, R. Derking, I. Bontjer, , M. van Gils
Abstract
The rapid spread of SARS-CoV-2 has a significant impact on global health, travel and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated neutralizing antibodies from convalescent COVID-19 patients using a SARS-CoV-2 stabilized prefusion spike protein. Several of these antibodies were able to potently inhibit live SARS-CoV-2 infection at concentrations as low as 0.007 {micro}g/mL, making them the most potent human SARS-CoV-2 antibodies described to date. Mapping studies revealed that the SARS-CoV-2 spike protein contained multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as previously undefined non-RBD epitopes. In addition to providing guidance for vaccine design, these mAbs are promising candidates for treatment and prevention of COVID-19.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike
L. Liu, P. Wang, … D. D. Ho·NaturePeer-reviewed·Jul 22, 2020
- Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals
S. J. Zost, P. Gilchuk, … J. E. Crowe·bioRxiv·May 22, 2020
- Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
S. J. Zost, P. Gilchuk, … J. E. Crowe·bioRxiv·May 12, 2020
- A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability
- A combination of RBD and NTD neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants
D. Haslwanter, M. E. Dieterle, … R. K. Jangra·mBioPeer-reviewed·Oct 26, 2021
- Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals
D. F. Robbiani, C. Gaebler, … Nuss·bioRxiv·May 13, 2020